Skip to main content

Table 1 Enrollment per study site in the survey and the prevention study

From: Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients

Country Study site ID Survey study Prevention study
All dogs A. vasorum positive Total
n n % n %
Denmark DA 50 19 38.0 31 5.0
DB 92 5 5.4 18 2.9
DD 15 0 0 9 1.4
DE 18 1 5.6 23 3.7
DF 23 2 8.7 29 4.7
DG 44 2 4.5 25 4.0
DH 1 0 0 0 0
DI 38 2 5.3 9 1.4
DJ 11 0 0 15 2.4
DK 10 5 50.0 9 1.4
DL 25 9 36.0 38 6.1
DM 52 1 1.9 37 5.9
DN 87 3 3.4 21 3.4
DO 42 7 16.7 13 2.1
DP 78 5 6.4 12 1.9
DR 22 6 27.3 30 4.8
Italy IA 83 5 6.0 23 3.7
IB 60 2 3.3 14 2.3
IC 82 5 6.1 20 3.2
ID 58 4 6.9 19 3.1
IE 82 12 14.6 25 4.0
IF 71 21 29.6 26 4.2
IG 79 15 19.0 38 6.1
IH 90 3 3.3 18 2.9
II 73 0 0 14 2.3
IJ 72 8 11.1 25 4.0
IK 49 9 18.4 17 2.7
IL 67 7 10.4 14 2.3
IN 82 29 35.4 30 4.8
IO 67 11 16.4 20 3.2
Total   1623 198 12.2 622 100
  1. Notes: For the survey study the total number of tested dogs and the number and percent of Angiostrongylus vasorum positive dogs is shown for each study site. For the prevention study the number and percent of all enrolled animals is provided per study site. Site DH withdrew from the studies